DAWN News and Press, Day One Biopharmaceuticals Inc. From 01/11/26

Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at ...

BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the succ...

2025-12-18 15:46:43 ET Investment Overview - Company & Q3 Earnings Overview - Reasons To Be Bullish Back in April 2024, I assigned Day One Biopharmaceuticals, Inc. ( DAWN ) stock a "Hold" rating in a note for the Seeking Alpha, covering the news that its lead asset tovor...

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening dis...

2025-12-10 10:26:49 ET Introduction AstraZeneca ( AZN ) is looking to be the first biopharma to throw off the cloak of cyclicality due to their work in optimizing the commercial and pipeline asset base. Despite being able to leverage experience and economies of scale, big pharma...

Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial 77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off therapy for at least 12 months The median time to next treatment (TTNT) following ini...

BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening dis...

2025-11-15 15:15:04 ET More on Blackstone, Parker-Hannifin, etc. Topgolf Callaway Brands' Catalyst Offers More Upside ABN AMRO Bank N.V. 2025 Q3 - Results - Earnings Call Presentation Merck & Co., Inc. (MRK) Presents at 7th Annual Healthcare Symposium Transcript ...

2025-11-13 14:54:25 ET The last time I spoke about Day One Biopharmaceuticals, Inc. ( DAWN ), it was in a Seeking Alpha article entitled "Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch." With respect to this article, I noted the opportunity that ...

2025-11-13 06:27:05 ET More on Day One Biopharmaceuticals, Mersana Therapeutics Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript Day One raises 2025 revenue guidance to $145M–$150M as OJEMDA sees sustained double-digit growth Goldman's ...